Zentalis Pharmaceuticals (ZNTL) Total Non-Current Liabilities (2022 - 2025)
Historic Total Non-Current Liabilities for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $73.9 million.
- Zentalis Pharmaceuticals' Total Non-Current Liabilities fell 2250.82% to $73.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.9 million, marking a year-over-year decrease of 2250.82%. This contributed to the annual value of $92.3 million for FY2024, which is 1796.62% down from last year.
- As of Q3 2025, Zentalis Pharmaceuticals' Total Non-Current Liabilities stood at $73.9 million, which was down 2250.82% from $76.7 million recorded in Q2 2025.
- Over the past 5 years, Zentalis Pharmaceuticals' Total Non-Current Liabilities peaked at $112.5 million during Q4 2023, and registered a low of $45.0 million during Q1 2022.
- Its 4-year average for Total Non-Current Liabilities is $92.5 million, with a median of $95.8 million in 2023.
- As far as peak fluctuations go, Zentalis Pharmaceuticals' Total Non-Current Liabilities skyrocketed by 12624.52% in 2023, and later plummeted by 2897.69% in 2025.
- Over the past 4 years, Zentalis Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $102.7 million in 2022, then rose by 9.6% to $112.5 million in 2023, then dropped by 17.97% to $92.3 million in 2024, then decreased by 19.96% to $73.9 million in 2025.
- Its Total Non-Current Liabilities was $73.9 million in Q3 2025, compared to $76.7 million in Q2 2025 and $88.1 million in Q1 2025.